NewsResearch
A New HER2 Lung Cancer Drug Gets Accelerated Approval: What That Means
The FDA's approval list shows sevabertinib cleared on an accelerated basis in September 2026 for HER2-mutated non-small cell lung cancer. Here is what a HER2 mutation is and why the word accelerated changes how to read the news.
Original commentary from the Cancer Explained editorial team.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
On the FDA's running list of cancer drug approvals, read on September 23, 2026, one September entry stands out for lung cancer. On September 9, 2026, sevabertinib (brand name Hyrnuo), described there as a kinase inhibitor, received accelerated approval for locally advanced or metastatic non-squamous non-small cell lung cancer with HER2 mutations.
Three parts of that sentence are worth unpacking: non-small cell lung cancer, HER2 mutation, and accelerated.
Non-small cell lung cancer, briefly
The National Cancer Institute describes non-small cell lung cancer as "a type of cancer that forms in the tissues of the lung," and notes it is more common than small cell lung cancer. It covers several forms, including adenocarcinoma, which starts in mucus-making cells, and squamous cell carcinoma, which starts in the flat cells lining the airways. The September approval is for the non-squamous group.
What a HER2 mutation is
HER2 is a protein that sits on the surface of cells and helps tell them when to grow. A mutation is a change in the gene that builds that protein — a typo in the instructions. When the typo leaves the protein stuck in the "grow" position, the cell keeps dividing when it should not.
A drug aimed at that specific fault is a targeted therapy. NCI defines targeted therapy as treatment that "targets proteins that control how cancer cells grow, divide, and spread," and calls it "the foundation of precision medicine."
The practical consequence is testing. NCI is blunt about this: "your tumor will need to be tested to see if it contains targets for which there is a drug." A lung cancer with a HER2 mutation looks no different from one without. Only a biomarker test — run on tumor tissue, sometimes on blood — tells you.
Many people will already have had this kind of testing, since NSCLC treatment planning routinely looks at genes such as EGFR and ALK. HER2 is another entry on that list.
Why "accelerated" is the important word
An accelerated approval is not a lesser approval, but it is an earlier one. It allows a drug to reach patients based on a measure expected to predict benefit — typically whether tumors shrank and for how long — rather than on completed evidence that people lived longer or better.
The confirming studies are supposed to continue after approval. Sometimes they confirm the benefit. Sometimes they do not, and the drug's approval for that use is withdrawn.
So the honest reading of a headline like this one is: a new option exists for a specific, tested group of people, and the full picture is still being assembled.
What this approval cannot tell you
- It cannot tell you how much longer anyone lives. That is the question an accelerated approval is granted before answering. The FDA's approval listing records the decision, not the survival data, and we did not read trial results for this page.
- It cannot tell you whether it applies to a particular person. It is written for non-squamous NSCLC with a HER2 mutation, locally advanced or metastatic. Without a test result, nobody knows whether that describes their cancer.
- It cannot tell you about side effects or daily life on the drug. None of that is in an approval listing, and it is a real part of any decision.
- It does not change anything about lung cancer screening or prevention. This is a treatment decision for people who already have a diagnosis.
What to ask a healthcare team
- Has my lung cancer had biomarker testing, and does the report mention HER2?
- If testing was done a while ago, is it worth repeating on newer tissue or on blood?
- Is this drug relevant to my situation, and where would it sit relative to what I am doing now?
- What is still unknown about it, and what would we watch to see if it is helping?
How this article was prepared
An AI-assisted editorial system helped prepare this page from the FDA's published oncology approval notifications list and National Cancer Institute patient pages on non-small cell lung cancer and targeted therapy, each opened on the source-check date shown above. No named medical reviewer has reviewed it unless one is listed.
Cancer Explained is published by the National Cancer Information Foundation. It is not medical advice and does not suggest a test or treatment.
See an error, old source, or unclear wording? Tell us.
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Put the story in context
Prevention, possible warning signs, screening, and diagnosis
This story relates to Lung cancer. The information below is general: it does not reveal anything else about a public person’s health, and not every point applies to every cancer. Personal advice depends on age, symptoms, family history, exposures, and medical history.
Prevention and risk reduction
Not every cancer can be prevented. Avoiding tobacco, protecting skin from ultraviolet radiation, limiting alcohol, staying active, and receiving recommended HPV or hepatitis B vaccination can lower the risk of certain cancers. A risk factor is not a prediction or a cause in one individual.
Symptoms and possible early signs
Possible signs vary and are often caused by conditions other than cancer. Changes worth discussing include a new lump, unexplained bleeding or weight loss, a persistent cough, lasting bowel or bladder changes, a changing skin spot, or symptoms that persist or worsen. Some early cancers cause no symptoms.
Screening and early detection
Screening looks for certain cancers before symptoms begin. Recommended tests exist only for some cancers and depend on age and risk. Screening can have benefits and harms; it is not the same as evaluating a new symptom, and there is no single routine scan or blood test that reliably screens for every cancer.
How cancer is diagnosed
Diagnosis may involve a history and exam, imaging, laboratory tests, and often a biopsy. Pathology can identify the cancer type and may test biomarkers that guide treatment. Symptoms, screening results, tumor markers, or online stories alone cannot confirm cancer.
Learn about this story’s cancer topic
A public story may encourage questions, but it should not be used to estimate your risk or choose testing. Contact a healthcare professional about a persistent or concerning change. Seek urgent care for severe or rapidly worsening symptoms.